Nevanimibe is primarily investigated for its potential therapeutic applications in treating endocrine disorders. It functions as an inhibitor of adrenal steroidogenesis, making it a candidate for managing conditions like Cushing's syndrome, where excessive cortisol production is a concern. By targeting specific enzymes involved in steroid hormone synthesis, it helps regulate abnormal hormone levels. Additionally, its properties are being explored in the context of certain cancers, particularly those driven by steroid hormone pathways, such as adrenocortical carcinoma. Research continues to evaluate its efficacy and safety in these clinical settings.